Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular

Item

http://www.wikidata.org/entity/Q26828860

Q26828860

about

Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group Lung cancer diagnosis and staging in the minimally invasive age with increasing demands for tissue analysis A review of clinical practice guidelines for lung cancer Molecular Diagnostics for Precision Medicine in Colorectal Cancer: Current Status and Future Perspective Molecular markers: Implications for cytopathology and specimen collection Identification of ABC Transporter Interaction of a Novel Cyanoquinoline Radiotracer and Implications for Tumour Imaging by Positron Emission Tomography Improving molecular testing and personalized medicine in non-small-cell lung cancer in Ontario KRAS Mutation Detection in Non-small Cell Lung Cancer Using a Peptide Nucleic Acid-Mediated Polymerase Chain Reaction Clamping Method and Comparative Validation with Next-Generation Sequencing.Molecular testing guidelines for lung adenocarcinoma: Utility of cell blocks and concordance between fine-needle aspiration cytology and histology samples.Quantitative proteomics in lung cancer.Non-Small Cell Lung Carcinoma Biomarker Testing: The Pathologist's Perspective Epidermal growth factor receptor (EGFR) mutations in small cell lung cancers: Two cases and a review of the literature Oncogene withdrawal engages the immune system to induce sustained cancer regression.Usage patterns of biomarkers in non-small-cell lung cancer patients in India: Findings from a systematic review and survey.Tumor genetic analyses of patients with metastatic renal cell carcinoma and extended benefit from mTOR inhibitor therapy Economic Impact of Tissue Testing and Treatments of Metastatic NSCLC in the Era of Personalized Medicine Accurate identification of ALK positive lung carcinoma patients: novel FDA-cleared automated fluorescence in situ hybridization scanning system and ultrasensitive immunohistochemistry Biomarker testing for breast, lung, and gastroesophageal cancers at NCI designated cancer centers.Current concepts on the molecular pathology of non-small cell lung carcinoma.An essential role for the immune system in the mechanism of tumor regression following targeted oncogene inactivation.Guidance for laboratories performing molecular pathology for cancer patients.Translating RNA sequencing into clinical diagnostics: opportunities and challenges.Relationship of thyroid transcription factor 1 to EGFR status in non-small-cell lung cancer.EGFR Mutation Positive Stage IV Non-Small-Cell Lung Cancer: Treatment Beyond Progression Melanoma genotypes and phenotypes get personal.Frequency of EGFR mutations in 907 lung adenocarcioma patients of Indian ethnicity.Next-generation sequencing of lung cancer EGFR exons 18-21 allows effective molecular diagnosis of small routine samples (cytology and biopsy).Clinicopathological characteristics of patients with non-small-cell lung cancer who harbor EML4-ALK fusion gene: a meta-analysis The use of a two-tiered testing strategy for the simultaneous detection of small EGFR mutations and EGFR amplification in lung cancer.EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey Challenges of coverage policy development for next-generation tumor sequencing panels: experts and payers weigh in.Multiplatform comparison of molecular oncology tests performed on cytology specimens and formalin-fixed, paraffin-embedded tissue.EGFR mutant allelic-specific imbalance assessment in routine samples of non-small cell lung cancer.Clinical Validation of Targeted Next Generation Sequencing for Colon and Lung Cancers.Effects of a Multidisciplinary Approach to Improve Volume of Diagnostic Material in CT-Guided Lung Biopsies.Comparison of next generation sequencing, SNaPshot assay and real-time polymerase chain reaction for lung adenocarcinoma EGFR mutation assessment.Determination of EGFR and KRAS mutational status in Greek non-small-cell lung cancer patients.Trefoil factor 3 as a novel biomarker to distinguish between adenocarcinoma and squamous cell carcinoma.Efficacy of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) in targeted therapy of lung squamous cell carcinoma patients with EGFR mutation: a pooled analysis.U.S. Food and Drug Administration Approval Summary: Ramucirumab for the Treatment of Metastatic Non-Small Cell Lung Cancer Following Disease Progression On or After Platinum-Based Chemotherapy.

P2860

Q26780457-229BAEDF-852D-46E1-B975-8AA5CE3094A8 Q26784085-87F7C91D-F9BE-4FAB-85B4-D16E79EBA92E Q26999236-AA0541BC-6B3C-4D13-9EDF-51A3E87F687C Q28070038-09C92E7E-380C-476C-A774-386271646913 Q28087155-6B0662C8-9857-41EA-8CC3-2FFE1EF84581 Q28553692-400C1559-D40C-4792-9FE1-2CA3E9D87FC0 Q33611088-4F396010-BB74-4109-BB9F-81FCFF13A0B7 Q33634165-DC3B630B-085C-41AF-8CDE-2327D5C9560E Q33760283-902B3608-CA2D-4AC5-B1FE-1735633CD638 Q33796358-FFCC9FB1-22B9-4E80-804A-595EF2209779 Q33906921-91D60100-3A77-46CC-B36B-6D9E4708B34E Q33925170-352503BB-59DF-45A5-8CB8-E5FC177716BD Q33987633-7CFF6875-65CB-48AD-891D-4BDF0BA22D15 Q34031517-AD2D3B3E-CAF6-46FA-BD07-BAC7DB290E28 Q34074997-6B25BAB8-C75F-42BA-9484-39580393DD45 Q34219452-380DBC46-0D70-453E-9C07-E1C4CF8A99E0 Q34231928-08AF3AAD-9069-4ABD-9417-C2C8951DBC38 Q34248282-651C71F5-9D08-40C5-8894-2BF02D72F1A1 Q34310062-0DE37538-0161-4853-B323-A7C1706B669C Q34361976-61E40DE1-CCF2-4BE5-894B-43EE1DB7CACF Q34431280-F94012E0-22DD-4108-AFD9-63BB0F1F0B58 Q34519034-1CD26583-6EB4-4856-834D-1B759032B37C Q34637846-FAC8FFDC-3218-46BB-A68F-A43A82C24298 Q34650994-D94BB0DC-AC53-4849-8129-90BC4F4208B3 Q34788817-F0A940DB-3862-4047-AAAB-6FAF7D82F3A0 Q35016912-A966B825-C316-4D2E-9C21-631BE6DBFFC7 Q35078128-4A5EF105-6A51-4686-B168-628B40541199 Q35113209-2F22DB79-289A-4A09-B5A4-CA38CE5B3311 Q35125795-07C1B384-4FA0-439A-856E-D7AA7D20E8CE Q35126110-D0CB325C-65B8-417F-83D8-A37FC12F75F8 Q35213023-CFA87B3F-F2C4-41D8-ADBB-D4E79AA40677 Q35237841-193B2A46-B2EB-42B0-9954-56B6FF1209C5 Q35654769-8D711200-DE7F-45E3-993B-4232A9EA7161 Q35772123-9510618C-05CF-4811-A30B-F7A79CDE386E Q35812150-517261BE-4A31-40E9-8CFC-84185F6CEA9B Q36027021-2CA9EA02-583F-431E-906B-07A39E0D3C40 Q36085452-A9CEB4DF-F364-4401-AD90-4641461A7AE6 Q36152945-1E67F5F2-DFCF-45C1-B0AB-A3C61AAD9891 Q36352476-15B0A3A1-A4BE-46D1-A7CE-449986E69089 Q36478734-D495D580-0893-4CCC-B1D3-52FED6E8CC03

P2860

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular

Item

http://www.wikidata.org/entity/Q26828860

description

2013 nî lūn-bûn

@nan

2013 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2013 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2013年の論文

@ja

2013年論文

@yue

2013年論文

@zh-hant

2013年論文

@zh-hk

2013年論文

@zh-mo

2013年論文

@zh-tw

2013年论文

@wuu

name

Molecular testing guideline fo ...... and Association for Molecular

@nl

type

Item

label

Molecular testing guideline fo ...... and Association for Molecular

@nl

prefLabel

Molecular testing guideline fo ...... and Association for Molecular

@nl

P1476

Molecular testing guideline fo ...... iation for Molecular Pathology

@en

P2093

David J. Kwiatkowski

http://www.w3.org/2001/XMLSchema#string

Dhananjay Arun Chitale

http://www.w3.org/2001/XMLSchema#string

Juan-Sebastian Saldivar

http://www.w3.org/2001/XMLSchema#string

Mary Beth Beasley

http://www.w3.org/2001/XMLSchema#string

Neal I. Lindeman

http://www.w3.org/2001/XMLSchema#string

Philip T. Cagle

http://www.w3.org/2001/XMLSchema#string

Robert Brian Jenkins

http://www.w3.org/2001/XMLSchema#string

Sanja Dacic

http://www.w3.org/2001/XMLSchema#string

P2860

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

Molecular epidemiology of EGFR and KRAS mutations in 3,026 lung adenocarcinomas: higher susceptibility of women to smoking-related KRAS-mutant cancers

Impact of epidermal growth factor receptor and KRAS mutations on clinical outcomes in previously untreated non-small cell lung cancer patients: results of an online tumor registry of clinical trials

Analysis of any point mutation in DNA. The amplification refractory mutation system (ARMS)

The COSMIC (Catalogue of Somatic Mutations in Cancer) database and website

MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib

Inhibition and facilitation of nucleic acid amplification

Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib.

P304

828-60

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1430529

http://www.w3.org/2001/XMLSchema#string

P356

10.5858/ARPA.2012-0720-OA

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

137

http://www.w3.org/2001/XMLSchema#string

P50

P577

2013-06-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

236102187

http://www.w3.org/2001/XMLSchema#string

P698

23551194

http://www.w3.org/2001/XMLSchema#string

P921

patient

P932

4162344

http://www.w3.org/2001/XMLSchema#string

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular

about

P2860

P2860

Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P3181

P356

P407

P433

P478

P50

P577

P5875

P698

P921

P932

P3181

P356

P1433

P1476

P2093

P2860

P304

P31

P3181

P356

P407

P433

P478

P50

P577

P5875

P698

P921

P932